Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growt...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Business Of Biotech
Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
Get summaries like this every morning.
Free AI-powered recaps of Business Of Biotech and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.